Thrombocytopenia with Tedizolid and Linezolid

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2017 Oct 18

PMID 29038274

Citations 24

Authors

Erica Yookyung Lee

Aisling R Caffrey

Affiliations

Soon will be listed here.

Abstract

Several studies have suggested the risk of thrombocytopenia with tedizolid, a second-in-class oxazolidinone antibiotic (approved June 2014), is less than that observed with linezolid (first-in-class oxazolidinone). Using data from the Food and Drug Administration adverse event reporting system (July 2014 through December 2016), we observed significantly increased risks of thrombocytopenia of similar magnitudes with both antibiotics: linezolid reporting odds ratio [ROR], 37.9 (95% confidence interval [CI], 20.78 to 69.17); tedizolid ROR, 34.0 (95% CI, 4.67 to 247.30).

Citing Articles

In vitro activity of tedizolid against 43 species of Nocardia species.

Toyokawa M, Ohana N, Tanno D, Imai M, Takano Y, Ohashi K Sci Rep. 2024; 14(1):5342.

PMID: 38438563 PMC: 10912709. DOI: 10.1038/s41598-024-55916-7.

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.

Zou F, Cui Z, Lou S, Ou Y, Zhu C, Shu C Front Pharmacol. 2024; 15:1338902.

PMID: 38434706 PMC: 10904462. DOI: 10.3389/fphar.2024.1338902.

New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians.

Carcione D, Intra J, Andriani L, Campanile F, Gona F, Carletti S Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765112 PMC: 10536666. DOI: 10.3390/ph16091304.

Effect of Platelet Parameters on Linezolid-Related Thrombocytopenia in Hospitalized Patients.

Zhang L, Yan Y, Liao R, Dong H Infect Drug Resist. 2023; 16:6145-6154.

PMID: 37719650 PMC: 10505032. DOI: 10.2147/IDR.S408102.

Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment.

Li B, Liu Y, Luo J, Cai Y, Chen M, Wang T Front Pharmacol. 2023; 14:1157437.

PMID: 37168994 PMC: 10165100. DOI: 10.3389/fphar.2023.1157437.

References

Moran G, Fang E, Corey G, Das A, De Anda C, Prokocimer P . Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014; 14(8):696-705. DOI: 10.1016/S1473-3099(14)70737-6. View

Ong V, Flanagan S, Fang E, Dreskin H, Locke J, Bartizal K . Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014; 42(8):1275-84. DOI: 10.1124/dmd.113.056697. View

Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y . Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010; 36(2):179-81. DOI: 10.1016/j.ijantimicag.2010.02.019. View

Brier M, Stalker D, Aronoff G, Batts D, Ryan K, OGrady M . Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003; 47(9):2775-80. PMC: 182634. DOI: 10.1128/AAC.47.9.2775-2780.2003. View

Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H . High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013; 68(9):2128-33. DOI: 10.1093/jac/dkt133. View

Evans S, Waller P, Davis S . Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2002; 10(6):483-6. DOI: 10.1002/pds.677. View

Bravata D, Olkin I . Simple pooling versus combining in meta-analysis. Eval Health Prof. 2001; 24(2):218-30. DOI: 10.1177/01632780122034885. View

Gerson S, Kaplan S, Bruss J, Le V, Arellano F, Hafkin B . Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002; 46(8):2723-6. PMC: 127358. DOI: 10.1128/AAC.46.8.2723-2726.2002. View

Sarangdhar M, Tabar S, Schmidt C, Kushwaha A, Shah K, Dahlquist J . Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol. 2016; 34(7):697-700. DOI: 10.1038/nbt.3623. View

10.

Lodise T, Fang E, Minassian S, Prokocimer P . Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother. 2014; 58(12):7198-204. PMC: 4249542. DOI: 10.1128/AAC.03509-14. View

11.

Prokocimer P, De Anda C, Fang E, Mehra P, Das A . Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013; 309(6):559-69. DOI: 10.1001/jama.2013.241. View

12.

van Puijenbroek E, Bate A, Leufkens H, Lindquist M, Orre R, Egberts A . A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002; 11(1):3-10. DOI: 10.1002/pds.668. View

13.

Attassi K, Hershberger E, Alam R, Zervos M . Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002; 34(5):695-8. DOI: 10.1086/338403. View

14.

Orrick J, Johns T, Janelle J, Ramphal R . Thrombocytopenia secondary to linezolid administration: what is the risk?. Clin Infect Dis. 2002; 35(3):348-9. DOI: 10.1086/341310. View